Lexaria Bioscience Corp.: Lexaria's Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new "DehydraTECH 2.0" cannabidiol ("CBD") formulations in its second 2021 applied research and development study program, HYPER-A21-2. "One of our latest DehydraTECH 2.0 formulations gave us the strongest absorption enhancement results we've ever recorded, at 2,708% more CBD into bloodstream during the study period than the representative industry standard MCT control formulation. It was also 174% more effective than the original DehydraTECH 2.0 formulation from 2019," said Chris Bunka, CEO of Lexaria. "This is a 27-fold improvement in CBD delivery compared to the control formulation."